
USA - NASDAQ:ONCE -
The current stock price of ONCE is 113.57 USD. In the past month the price increased by 2.49%. In the past year, price increased by 206.86%.
Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Onconetix Inc
3737 MARKET STREET SUITE 1300
PHILADELPHIA PA 19104
CEO: Jeffrey D. Marrazzo
Phone: 888-772-7560
Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
The current stock price of ONCE is 113.57 USD. The price increased by 2.55% in the last trading session.
ONCE does not pay a dividend.
ONCE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Onconetix Inc (ONCE) has a market capitalization of 4.38B USD. This makes ONCE a Mid Cap stock.
ChartMill assigns a technical rating of 8 / 10 to ONCE. When comparing the yearly performance of all stocks, ONCE is one of the better performing stocks in the market, outperforming 98.44% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ONCE. While ONCE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ONCE reported a non-GAAP Earnings per Share(EPS) of -6.56. The EPS decreased by -202.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -358.41% | ||
| ROA | -35.6% | ||
| ROE | N/A | ||
| Debt/Equity | 0.35 |